Skip to main content

Advertisement

11β Hydroxysteroid dehydrogenase – 1 activity in type 2 diabetes mellitus: a comparative study

BMC Endocrine Disorders volume 19, Article number: 15 (2019) Cite this article

Abstract

Background

A comparative study of 11 β HSD 1 activity in type 2 diabetes mellitus subjects with respect to fasting blood glucose and other metabolic parameters was conducted.

Methods

A case control experimental study was performed enrolling thirty type 2 diabetes mellitus patients and thirty age, gender and BMI matched controls using cortisone acetate test.

Results

The rise of serum cortisol after oral 25 mg cortisone acetate from baseline (dexamethasone suppressed level) is higher in subjects with type 2 diabetes and is associated with exercise, BMI, SGOT but not daily calorie intake, lipid parameters and thyroid status. Fasting blood glucose after overnight 1 mg oral dexamethasone is a strong predictor of 11HSD1 activity, irrespective of presence of type 2 diabetes.

Conclusion

11β HSD 1 activity is higher in type 2 diabetes mellitus subjects, especially those who are lean. Future 11 β HSD 1 inhibitors targeting metabolic syndrome, will be most useful in those with increased fasting blood glucose. The role of DHEAS and vitamin D status needs to be explored.

Open Peer Review reports

Background

The enzyme 11 β HSD is a bi-functional enzyme with activity dependent on NAD(H)/NAD ratio. Type 1 activity of 11βHSD implies cortisone (E) to cortisol (F) conversion. Cortisol generated by 11βHSD1 in hepatocytes can increase hepatic glucose output by activating transcription of phosphoenol pyruvate kinase (PEPCK). This increase in hepatic glucose output occurs independent of any interaction with insulin, glucagon or free fatty acids (FFA) [1].Transgenic mice over expressing 11βHSD1 develop metabolic syndrome but not obesity. This has lead to the hypothesis that type 2 diabetes mellitus is a form of localized Cushings syndrome [2].This experimental study compares 11β HSD1 activity between type 2 diabetes mellitus patients and healthy controls. This study also correlates 11βHSD1 activity with various metabolic parameters in each group. We devised a unique protocol of cortisone acetate test to estimate 11βHSD1 activity. The test has been described previously [3].

Methods

The study was carried out in 2014–2015 and Test protocol as described below was approved by Institutional Ethics Committee (IEC) of Kolkata Medical College, India. The objective was to assess 11βHSD1 activity in cases and compare it with healthy controls. Thirty subjects with type 2 diabetes and thirty healthy controls were selected for the study. Cases were selected from those attending outpatient services of Department of Endocrinology Medical College Kolkata, while healthy controls were selected from those volunteering for the study. The sample size calculated using formulae:

Sample size = Z × S.D./d2 where.

Z = standard normal variate at 1.96.

S.D. = 4.5 μg/dl based on pharmacokinetic absorption data of cortisone acetate.

d = precision = 3 based on previous study on type 1 DM [3] Those with known diabetic complications and HbA1c > 7 mmol/l or random blood glucose > 200 mg/dl in preceding 7 days were excluded. Healthy subjects were chosen from those volunteering for the study.

Cortisone acetate test protocol

All subjects were admitted a day before testing and were given 1 mg dexamethasone at 11 pm. Next day, 8:00 am fasting blood glucose and serum cortisol sample was taken. Thereafter, tablet cortisone acetate (25 mg) was given with standardized breakfast of two brown bread slices. Second sample of serum cortisol was taken at 8 45 am. The difference between the cortisol values was denoted as delta cortisol. Delta cortisol is two taken as surrogate of 11βHSD1 activity .

Roche COBAS e411 (Co-efficient of variation < 10%) was used for measurements of serum cortisol, TSH, free T4, TT4, 25(OH) vitamin D. CENTAUR was used for lipid profile and other investigations. NHAMS and NIN-ICMR guidelines were followed for anthropometry and daily dietary calorie calculation, respectively. Physical activity, BMI, and calorie intake was categorized (see Additional file 1). Kolmogorov-Smironoff and Shapiro Wilk tests were used to check normality. Students t test, one way & two way ANOVA, Mann-Whitney U test, Friedmen test, Kruskal Wallis tests were used for in between groups comparison. Wilcoxen Signed Rank test was used to compare pre & post dexamethasone fasting blood glucose. The Pearson & Spearmen test was used to test association between variables. A multiple regression analysis model was used to find out various parameters affecting delta cortisol activity. SPSS software version 20 was used for statistical analysis.

Results

Study subjects were well matched for age & weight (Table 1). Metabolic parameters were compared using t-test and Mann-Whitney test as described in Table 2 . All subjects (except one diabetic subject) had dexamethasone suppressed cortisol level < 1.8 mcg/dl. There was no statistically significant difference between diabetic and non diabetic subjects in 8 00 h serum cortisol level. (p = 0.211, Mann-Whitney test) (Table 3). The 11 β HSD1 activity in diabetes subjects was found to be significantly increased (p = 0.022, Mann-Whitney test) as compared to controls (Table 3).

Table 1 Characteristics of Diabetes and Healthy controls
Full size table
Table 2 Fasting lipid profile, liver & renal function tests of the study subjects
Full size table
Table 3 Hormonal evaluation of study subjects
Full size table

In study subjects < 35 years of age, 11β HSD1 activity was significantly increased in diabetics as compared to healthy controls (Table 4, Fig. 1) [p = 0.005, Mann-Whitney test]. In other age groups, 11β HSD1 activity was not statistically different between diabetics and controls (Table 4, Fig. 1). Similarly, in subjects who exercise > 180 min/week, 11β HSD1 activity was found to be significantly more in diabetics (Table 4, Fig. 2) (p = 0.004, Mann-Whitney test). Diabetes subjects with BMI < 23 kg/m2 had significantly higher 11β HSD1 activity as compared to healthy controls (Table 4) (p = 0.017, Mann-Whitney test). There was no effect of calorie intake on 11β HSD1 activity (Table 4, Fig. 3) .

Table 4 Comparison of delta cortisol in diabetes subjects and control
Full size table
Fig. 1
figure1

Delta cortisol according to age groups. 11β HSD1 activity was increased in young(< 35 years) diabetics but not older (> 35 years), when compared to healthy controls

Full size image
Fig. 2
figure2

Delta cortisol in those who exercise. Diabetics who exercise > 180 min/week have higher 11β HSD1 activity

Full size image
Fig. 3
figure3

Delta cortisol according to calorie groups. Higher 11β HSD1 activity seen in diabetics with lower calorie intake, but was not statistically significant when Kruskal Wallis test was applied (p = 0.08)

Full size image

11β HSD1 activity was inversely associated with waist circumference (p = 0.027, rho = − 0.356, Pearsons correlation) in diabetics, albeit weakly. SGOT was significantly increased in diabetes and was strongly associated with 11β HSD1 activity in diabetes subjects {spearman rho = 0.638, p = 0.002). Fourteen diabetes subjects had finding of fatty liver on sonography. Post dexamethasone FBG was significantly raised in subjects with diabetes (p = 0.01, Wilcoxen Signed Rank test) but not healthy controls. 11β HSD1 activity was strongly correlated with post dexamethasone FBG in both cases and controls. Even after adjusting for increased FBG in diabetics, post dexamethasone FBG correlated with delta cortisol. Curiously, the same association was not observed with pre dexamethasone FBG. LDL was significantly associated with 11β HSD1 activity in healthy controls but not diabetics.

11βHSD1 activity was analysed separately in diabetes and healthy participants using Spearman correlation (Table 5). In diabetics, 11βHSD1 activity was found to be associated with SGOT(p = 0.02), alkaline phosphatase (ALP) (p = 0.03), FBG(p = 0.008). In healthy subjects, it was found to be associated with systolic blood pressure (p = 0.013), LDL (p = 0.006), triglycerides. Age, BMI, TSH and daily calorie intake had no effect on 11βHSD1 activity. Multiple regression analysis was performed to predict 11β HSD1 activity using automatic linear modeling, with 11β HSD1 activity being taken outcome variable using forward stepwise model building method. Five variables were identified at p < 0.05 (Table 6).

Table 5 Delta cortisol analysed separately for cases and control
Full size table
Table 6 Results of linear regression using automated linear model
Full size table

Discussion

Cortisone acetate test has been previously described for measuring 11β HSD1 activity [3].We added overnight dexamethasone suppression, so as to bring 0800 h basal cortisol at similar levels in the study subjects. It has been shown that serum cortisol levels attained 45 min after cortisone acetate ingestion is entirely due to 11 β HSD1 activity [4]. Hence, endogenous cortisol secretion acting as confounder, is ruled out. Delta cortisol can thus be used as surrogate marker of 11βHSD1 activity in splanchanic circulation, more specifically liver [5].

Increased 11βHSD activity could lead to development of metabolic syndrome [6].11 β HSD knock off transgenic mice have higher insulin sensitivity. They are also resistant to develop metabolic syndrome when put on high fat diet [7]. An 11 β HSD1 inhibitor has been shown to reverse metabolic syndrome in mice over expressing 11βHSD1 [8].This has lead to the hypothesis that increased 11 β HSD1 activity has a contributory role in development of type 2 diabetes/metabolic syndrome. A study carrying out cortisone acetate test in young type 1 diabetes subjects reported decreased 11βHSD 1 activity and inverse correlation was found with insulin dose requirement. The decreased 11 β HSD1 was attributed to insulin [4] .Insulin directly inhibits 11 β HSD1 activity in liver [9].Insulin resistance would similarly increase 11 β HSD 1 activity. It would be imperative to compare our results with those studies that evaluated 11 β HSD by other methods e.g. Urinary tetrahydrocortisol (THF) + allo-THF: tetrahydrocortisone (THE) ratio [10]. An increased ratio means relative decrease in cortisol inactivation i.e. increased 11β HSD1. Studies using (THF + allo-THF): THE ratio have not found any difference with respect to type 2 DM [11] except one [12]. However, the method of using THF_allo-THF: THE ratio has an inherent fallacy. The cortisol- cortisone metabolism is likely affected by differences in 5alfa/5 β reductase enzyme activities and this can lead to erroneous conclusion [12]. One study using cortisone acetate test to estimate 11βHSD1 activity in type 2 diabetes found it to be decreased, but baseline cortisol was not suppressed [6]. Studies examining 11βHSD activity in diabetes patients by 11 β HSD1 mRNA in skeletal tissue have found it to be increased in diabetes [13]. Previous report of decreased post dexamethasone 9 00 h cortisol as compared to controls [6] has not been confirmed in our study, possibly because we used 1 mg instead of 0.25 mg dexamethasone.

In humans, the 11 β HSD1 activity differs with age. Cortisone acetate is ineffective in treating congenital adrenal hyperplasia (CAH) in children less than 2 years of age, suggesting decreased 11βHSD1 activity in younger age [14]. Growth hormone (GH) inhibits 11βHSD1 and with decreasing GH levels, 11β HSD1 activity is increased in elderly [15]. 11βHSD1 activity was compared in three age groups: < 35 years, 35–50 yrs., > 50 yrs. These groups were determined in taking into consideration DHEAS levels, which vary greatly in age groups defined above. DHEAS is an inhibitor of 11βHSD1 enzyme in human adipocytes in vitro [16] . In age group < 35 years, diabetics had higher 11βHSD1 activity as compared to healthy individuals. This was not due to duration of diabetes, as there was no significant difference in 11β HSD 1 activity with diabetes duration. DHEAS levels are higher in young adults and decline precipitously in third decade (so called adrenopause). We speculate that decreased DHEAS levels/ premature adrenopause has lead to increased 11β HSD1 activity in diabetics < 35 years of age. As there is no precedent study examining 11β HSD1 with DHEAS, the matter cannot be concluded. 11 βHSD1 in vivo shows sexual dimorphism with males having higher higher activity [17]. We did not find any difference, possibly due skewed gender distribution of study subjects.

Effect of exercise

11 β HSD1 activity was significantly increased in those diabetes subjects, who exercise as compared to healthy subjects with same range of physical activity. However, in those with sedentary or lower level of physical activity, no difference in 11βHSD1 activity was observed. Acute intense physical activity leads to increased 11βHSD1 activity [18].The effect of chronic physical activity on 11βHSD1 has been less adequately studied. Chronic physical exercise induces Nuclear Factor kappa B (NFkB) activation and increased transcription in adult males [19]. NFkB has been found to induce 11βHSD1 activity under hypoxic conditions [20].Increased cellular hypoxia can thus lead to increased 11βHSD1 activity. Exercise induces hypoxia in skeletal muscle due to increased demand for ATP. It can be therefore hypothesized that diabetic subjects had ‘maladapted’ cellular energetics leading to increased 11 β HSD1 activity on > 180 min/week of exercise. Increased mitogenesisis of arterial smooth muscle cell is a feature of insulin resistense. It is accompanied by increased NFkB activity and higher SBP [21] . Diabetic subjects who exercised had increased systolic blood pressure (SBP) as compared to controls. This paradox of increased blood pressure with exercise can be explained by NFkB induced 11β HSD1 activity .

Both BMI and waist circumference were well matched in cases and controls. Diabetes subjects with normal weight (i.e < 23 kg/m2) were found to have significantly higher 11β HSD1 activity not only compared to controls, but also compared with those diabetics with BMI > 23 kg/m2. As no standards for ‘normal’ delta cortisol exist, the above statement could mean decreased 11 β HSD1 activity in healthy subjects rather than increased activity in diabetics. Indeed decreased 11 β HSD1 activity has been postulated as an adaptation to protect from adverse metabolic effect of obesity in Zucker diabetic rats [22]and possibly in humans [11]. Those who fail to downregulate 11βHSD1 activity develop diabetes, hypertension and dyslipidemia. Decreased 11βHSD1 activity might protect healthy controls from diabetes. However, this adaptation was lost at BMI > 23. At BMI greater than 23, 11βHSD1 activity was similar in cases and control. This indicates that after a certain degree of obesity (which in our population is BMI > 23), other factors i.e. insulin resistance take precedence in causation of diabetes, hypertension and dyslipidemia. Atleast one selective 11 β HSD1 inhibitor has entered phase 3 trial [23]. On basis of this study,a hypothetical target group for 11 β HSD1 inhibitor would be those with BMI < 23 kg/m2 - The “thin fat Indian” phenotype.

Waist circumference was inversely correlated with 11βHSD1 activity in diabetes i.e. increased waist circumference was associated with decreased 11 β HSD1 activity. Waist circumference represents visceral adipose tissue (VAT) more closely. The VAT has almost exclusively cortisol (F) to cortisone(E) conversion (i.e. 11β HSD2 actvity). As a result the substrate cortisone (E) is generated through VAT is presented to liver for localized cortisol generation [5]. 11 β HSD, too, is located around portal venules in the liver [24]. However in subjects with higher VAT, there is relative increase in 11β HSD1 activity of visceral fat and decrease in liver 11 β HSD1 activity. This “compensatory” decrease in liver 11βHSD1 activity is what our test measured. It could be due to adipokines [6]. In those with gynoid fat distribution visceral tissue 11βHSD1 is decreased [25].

Both systolic and diastolic blood pressure was associated with increased 11 β HSD1 activity in controls but not in diabetics, possibly because of confounding effect of anti-hypertensives. Cortisol- cortisone shuttle regulated by 11 β HSD1 activity plays role in increased vascular tone, more so in clinical states of primary aldosteronism (where diastolic hypertension is prominent) and Cushing syndrome [26]. Mice over expressing 11βHSD1 have severe hypertension due to increased angiotensinogen generation by the liver [27] . Our study finds the association for the first time in normotensive healthy adults.

Two FBG values were available for each patients. Matching FBG could not be possible in two groups. Dexamethasone significantly increased FBG in diabetic patients but not healthy controls. 11 β HSD1 activity was strongly associated with FBG in both cases and control. Linear modeling showed that even after adjusting for the presence of diabetes, post dexamethasone FBG was associated with increased 11 β HSD1 activity. The same association was not found with pre dexamethasone FBG. This points to a possible influence of dexamethasone itself on 11βHSD1 activity. Dexamethasone has been shown to induce 11β HSD 1 gene transcription both directly and indirectly. Direct action takes days, while indirect action takes minutes to manifest. Indirect action occurs by binding to P2 promotor region, located upstream to HSD11B1 gene [28, 29].

LDL was well matched in cases and controls. But only in healthy subjects, 11 HSD1 activity was associated with LDL. We attribute lack of association of 11 β HSD1 activity with LDL in diabetes subjects to concomitant statin use. Since statins suppress low grade inflammation of chronic diseases, they could well have inhibitory effect on 11 β HSD1 activity. We could not relate 11β HSD1 activity with triglycerides. Glucocorticoids increase total cholesterol, LDL, HDL, but major increase is in triglycerides [30].Thus, there is diversion between glucocorticoid (GC) receptor action and 11βHSD1 activity on lipid metabolism. This can be explained by non-genomic action of glucocorticoids on TG synthesis pathway, circumventing 11 β HSD enzyme. NAFLD is widely considered as hepatic manifestation of metabolic syndrome. Previous studies have documented derangement of cortisol metabolism, i.e. increase localized liver glucocorticoid action [31]. Systemic hypercortisolemia of Cushings disease ironically protects from hepatic steatosis, and glucocorticoids have therapeutic benefit in alchoholic hepatitis. Altered 11βHSD1 activity might be one of the reason [32]. SGOT was strongest predictor of 11 β HSD1 activity on multiple regression. Since SGOT/SGPT ratio is increased in non alchoholic steatohepatitis (NASH), we speculate role of 11 β HSD1 activity as determining factor in fatty liver to NASH progression.

Although serum alkaline phosphatase (ALP) was significantly increased in diabetics, no association with 11 β HSD1 activity was found after multiple regression. The 11β HSD1 activity is present in both osteoclasts and osteoblasts. Invitro studies have shown increased 11 β HSD1 activity to be associated with bone reabsorption markers including ALP [33]. Firstly, increased ALP levels in diabetics can be due to more prevalent vitamin D deficiency [34, 35].Secondly, although ALP is bone turnover marker and bone turnover markers are associated with 11βHSD1 activity, it is premature to draw any conclusion in the absence of other bone turnover markers. Thirdly, increased ALP in diabetics who undertake rigorous physical activity might be due to subtle trauma, microfractures and osteoarthritis. Fourthly, the test was not for bone specific ALP. TSH was evaluated in the two the groups and no significant association was found with 11βHSD1 activity.

Conclusion

We compared 11β HSD1 activity in type 2 diabetes subjects with healthy controls using a novel protocol of cortisone acetate test. 11βHSD1 activity is increased in type 2 diabetes mellitus, those with diabetics with BMI < 23 kg/m2, and those who engage in regular exercise. It is also associated with hepatic enzyme elevation,systolic blood pressure and possibly with DHEAS and vitamin D deficiency. There exists a dichotomy between glucocorticoid action and 11β HSD1 activity in lipoprotein metabolism. Fasting blood glucose, especially after overnight dexamethasone is a strong determinant of 11β HSD1 activity and can be used as its surrogate marker. Future 11βHSD1 inhibitors targeting metabolic syndrome will be most useful in those with increased fasting blood glucose. .

Abbreviations

ALP:

Alkaline phosphatase

BMI:

Body Mass Index

DHEAS:

Dihydroxyepiandrostenedionesulphate

FBG:

Fasting blood glucose

HSD:

Hydroxysteroiddehydrogenase

NAD (P):

Nicotinamideadenine dinucleotide phosphate

NAD:

Nicotinamide adenine dinucleotide

NAFLD:

Nonalchoholic fatty liver disease

NFkB:

Nuclear Factor kappaB

PEPCK:

Phosphoenol pyruvate kinase

SGOT:

SerumGlutamate oxaloacetate transferase

SGPT:

Serum Glutamate PyruvateTransferase

TG:

Triglycerides

THE:

Tetrahydrocortisone

THF:

Tetrahydrocortisol

TSH:

Thyroid Stimulating Hormone

VAT:

Visceral Adipose Tissue

WC:

Waist circumference

References

  1. 1.

    Edgerton DS, Basu R, Ramnanan CJ, Farmer TD, Neal D, Scott M, Jacobson P, et al. Effect of 11 beta-hydroxysteroid dehydrogenase-1 inhibition on hepatic glucose metabolism in the conscious dog. Am J Physiol Endocrinol Metab. 2010 May;298(5):E1019–26.

  2. 2.

    Paterson JM, Morton NM, Flevet C, Holmes MC, Staels B, Holmes MC, et al. Metabolic syndrome without obesity: hepatic over expression of 11β-hydroxysteroid dehydrogenase type 1 in transgenic mice. Proc Natl Acad Sci U S A. 2004;101:7088–93.

  3. 3.

    Šimunkova HR, Hill M, Kriz L, Vrbkova J, Kvasnickova H, Vondra K. Evaluation of hepatic 11 β-Hydroxysteroid dehydrogenase activity by cortisone acetate test in young adults with diabetes mellitus Type1. Physiol Res. 2011;60:263–70.

  4. 4.

    Andrew R, Smith K, Jone GC, Walker BR. Distinguishing the activities of 11 β-hydroxysteroid dehydrogenases in vivo using isotopically labeled cortisol radiotracer. J Clin Endocrinol Metab. 2002;87:277–85.

  5. 5.

    Basu R, Singh RJ, Basu A, Chittilapilly EG, Johnson CM, Toffolo G, et al. Splanchnic cortisol production occurs in humans – evidence for conversion of cortisone to cortisol via the 11-beta hydroxysteroid dehydrogenase type 1 pathway. Diabetes. 2004;53:2051–9.

  6. 6.

    Robert C, Andrew S, Olive H, Dawn EWL, Ruth A, Walker BR. Abnormal cortisol metabolism and tissue sensitivity to cortisol in patients with glucose intolerance. J Clin Endo Metab. 2002;87(12):5587–93.

  7. 7.

    Kotelevtsev Y, Holmes MC, Burchell A, Houston PM, Schmoll D, Jamieson P, et al. 11 β-Hydroxysteroid dehydrogenase type 1 knockout mice show attenuated glucocorticoid-inducible responses and resistant hyperglycemia on obesity or stress. Proc Natl Acad Sci U S A. 1997;94:14924–9.

  8. 8.

    Hermanowski-Vosatka A, Balkovec JM, Chenk K, Cheng HY, Hernandez M, Koo GC, et al. 11Beta-HSD1 inhibition ameliorates metabolic syndrome and prevents progression of atherosclerosis in mice. J Exp Med. 2005;202:517–27.

  9. 9.

    Putignano P, Pecori GF, Cavagnini F. Tissue-specific dysregulation of 11ß-hydroxysteroid dehydrogenase type 1 and pathogenesis of the metabolic syndrome. J Endocrinol Investig. 2004;27:969–74.

  10. 10.

    Palermo M, Shackleton CH, Mantero F, Stewart PM. Urinary free cortisone and the assessmentof 11ß -hydroxysteroid dehydrogenase activity in man. Clin Endocrinol. 1996;45:605–11.

  11. 11.

    Kerstens MN, Riemens SC, Sluiter WJ, Pratt JJ, Wolthers BG, Dullaart RP. Lack of relationship between 11ßhydroxysteroid dehydrogenase set point and insulin sensitivity in the basal state and after 24 h of insulin infusion in healthy subjects and type 2 diabetic patients. Clin Endocrinol. 2000;52:403–11.

  12. 12.

    Agha A, Monson JP. Modulation of glucocorticoid metabolism by the growthhormone–IGF-1 axis. Clin Endocrinol. 2007;66:459–65.

  13. 13.

    Abdallah BM, Beck-Nielsen H, Gaster M. Increased expression of 11 beta-hydroxysteroid dehydrogenase type 1 in type 2 diabetic myotubes. Increased expression of 11 beta-hydroxysteroid dehydrogenase type 1 in type 2 diabetic myotubes. Eur J Clin Investig. 2005;35(10):627–34.

  14. 14.

    Jinno K, Sakura N, Nomura S, Fujitaka M, Ueda K, Kihara M. Failure of cortisone acetate therapy in 21-hydroxylase deficiency in early infancy. Pediatr Int. 2001;43:478–82.

  15. 15.

    Toogood AA, Taylor NF, Shalet SM, Monson JP. Sexual dimorphism of cortisol metabolism is maintained in elderly subjects and is not estrogen dependent. Clin Endocrinol. 2000;52:61–6.

  16. 16.

    McNelis JC, Manolopoulos KN, Gathercole LL, Bujalska IJ, Stewart PM, Tomlinson JW, Arlt W. Dehydroepiandrosterone exerts antiglucocorticoid action on human preadipocyte proliferation, differentiation, and glucose uptake. Am J Physiol Endocrinol Metab. 2013;305:e1134–44.

  17. 17.

    Raven PW, Taylor NF. Steroid metabolism in healthy men and women. J Endocrinol. 1995;147(Suppl. 2):100.

  18. 18.

    Dovio A, Roveda E, Sciolla C, Montaruli A, Raffaelli A, Saba A, et al. Intense physical exercise increases systemic 11beta-hydroxysteroid dehydrogenase type 1 activity in healthy adult subjects. Eur J Appl Physiol. 2010;108(4):681–7.

  19. 19.

    Vider J, Laaksonen D, Kilk A, Atalay M, Lehtmaa J, Zilmer M, et al. Physical exercise induces activation of NF-κB in human peripheral blood lymphocytes. Antioxid Redox Signal. 2004;3(6):1131–7.

  20. 20.

    Lee JH, Gao Z, Ye J. Regulation of 11β-HSD1 expression during adipose tissue expansion by hypoxia through different activities of NF-k band HIF. Am J Physiol Endocrinol Metab. 2013;304:e1035–41.

  21. 21.

    Kim F, Pham M, Luttrell I, Bannerman DD, Tupper J, Thaler J, Hawn TR, Raines EW, Schwartz MW. Toll like receptor-4 mediates vascular inflammation and insulin resistance in diet-induced obesity. Circ Res. 2007;100:1589–96.

  22. 22.

    Morton NM, Ramage L, Seckl JR. Down-regulation of adipose 11 beta hydroxysteroid dehydrogenase type 1 high-fat feeding in mice: a potential adaptive mechanism counteracting metabolic disease. Endocrinology. 2004;145:2707–12.

  23. 23.

    Rosenstock J, Banarer S, Fonseca VA, et al. The 11-beta-hydroxysteroid dehydrogenase type 1 inhibitor INCB13739 improves hyperglycemia in patients with type 2 diabetes inadequately controlled by metformin monotherapy. Diabetes Care. 2010;33:1516–22.

  24. 24.

    Ricketts ML, Verhaeg JM, Bujalska I, Howie AJ, Rainey WE. Stewart PM Immunohistochemical localization of type 1 11β-hydroxysteroid dehydrogenase in human tissues. J Clin Endocrinol Metab. 1998;83:1325–35.

  25. 25.

    Stewart PM, Boulten A, Kumar S, Clark P, Shackelton C. Cortisol metabolism in human obesity: impaired cortisone to cortisol conversion in subjects with central adiposity. J Clin Endocrinol Metab. 1999;84:1022–7.

  26. 26.

    Walker BR, Connacher AA, Webb DJ, Edwards CR. Glucocorticoids and blood pressure: a role for the cortisol/cortisone shuttle in the control of vascular tone in man. Clin Sci. 1992;83:171–8.

  27. 27.

    Masuzaki H, Yamamoto H, Kenyon CJ, Elmquist JK, Morton NM, Paterson JM, Shinyama H, Sharp MG, Fleming S, Mullins JJ, Seckl JR, Flier JS. Transgenic amplification of glucocorticoid action in adipose tissue causes high blood pressure in mice. J Clin Invest. 2003;112:83–90.

  28. 28.

    Rajan V, Edwards CR, Seckl JR. 11 beta-Hydroxysteroid dehydrogenase in cultured hippocampal cells 11-dehydrocorticosterone, potentiating neurotoxicity. J Neurosci. 1996;16:65–70.

  29. 29.

    Seckl JR, Chapman KE. A novel promoter for the 11beta-hydroxysteroid dehydrogenase type 1 gene is active in lung and is C/EBP alpha independent. Endocrinology. 2006;147:2879–85.

  30. 30.

    Marais AD. Lipids, lipoprotein metabolism and their derangements. Heart. 2005;2(3):8–18.

  31. 31.

    Gastaldelli A. Fatty liver disease: the hepatic manifestation of metabolic syndrome. Hypertens Res. 2010;33:546–7.

  32. 32.

    Tarantino G, Finelli C. Pathogenesis of hepatic steatosis: the link between hypercortisolism and non-alcoholic fatty liver disease. World J Gastroenterol. 2013;19(40):6735–43.

  33. 33.

    Cooper MS, Walker EA, Bland R, Fraser WD, Hewison M, Stewart PM. Expression and functional consequences of 11b-Hydroxysteroid dehydrogenase activity in human bone. Bone. 2000;27:375–81.

  34. 34.

    Dutta D, Maisnam I, Shrivastava A, Sinha A, Ghosh S, Mukhopadhyay P, et al. Serum vitamin-D predicts insulin resistance in individuals with prediabetes. Indian J Med Res. 2013;138:853–60.

  35. 35.

    Maxwell DB, Fisher EA, Ross-Clunis HA 3rd, Estep HL. Serum alkaline phosphatase in diabetes mellitus. J Am Coll Nutr. 1986;5(1):55–9.

Download references

Acknowledgements

The authors thank RSSDI for grant of 50000 INR for logistics of the project. The fund was used towards purchase of serum cortisol kit for the project.

Consent to participate

Study participants gave written consent to participate and publish.

Funding

This project was partially funded by Research Society for study of Diabetes(RSSDI) in India grant as acknowledged below. The RSSDI had no role in study, collection, analysis, interpretation, and writing of manuscript.

Availability of data and materials

Raw dataset to be made available on request to corresponding author in excel file.

Author information

Affiliations

  1. Department of Endocrinology & Metabolism, AIIMS, Jodhpur, 342005, India
    • Ravindra Shukla
  2. Medical College Kolkata, Kolkata, India
    • Asish Kumar Basu
    • , Biplab Mandal
    • , Animesh Maity
    • , Satyam Chakraborty
    •  & Praveen Kumar Devrabhai
  3. IPGMER, Kolkata, India
    • Pradip Mukhopadhyay
Authors
  1. Search for Ravindra Shukla in:
  2. Search for Asish Kumar Basu in:
  3. Search for Biplab Mandal in:
  4. Search for Pradip Mukhopadhyay in:
  5. Search for Animesh Maity in:
  6. Search for Satyam Chakraborty in:
  7. Search for Praveen Kumar Devrabhai in:

Contributions

RS hypothesized, designed study and wrote manuscript. AB &BM made critical revisions in discussion,interpretation and conclusion and thus helped in writing the manuscript. PM& SC helped with data research. PD, AM helped in test standardization.All authors have read and approved the final manuscript.

Corresponding author

Correspondence to Ravindra Shukla.

Ethics declarations

Competing interest

The authors disclose that there is no conflict of interest financial or otherwise with regard to the study

Ethics approval and consent to participate

The study was approved by Independent Ethics Committee (IEC) of Medical College, Kolkata,India under West Bengal University of Health Sciences(WBUHS). The ethics committee no is ECR/287/Inst/WB/2013/RR-16.

Consent for publication

Not Applicable. See above.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Additional file

Additional file 1:

Categorization of study subjects (DOCX 13 kb)

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Shukla, R., Basu, A.K., Mandal, B. et al. 11β Hydroxysteroid dehydrogenase – 1 activity in type 2 diabetes mellitus: a comparative study. BMC Endocr Disord 19, 15 (2019). https://doi.org/10.1186/s12902-019-0344-9

Download citation

Keywords

  • 11 β HSD 1
  • Type 2 diabetes mellitus
  • Cortisone acetate test

BMC Endocrine Disorders

ISSN: 1472-6823

Contact us